CAM
ALXO icon

Connacht Asset Management’s ALX Oncology ALXO Stock Holding History

Connacht Asset Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20,953
Closed -$170K – 122
2022
Q2 		$170K Buy
20,953
+4,788
+30% +$52.1K 0.07% 145
2022
Q1 		$273K Buy
16,165
+5,841
+57% +$99.7K 0.14% 112
2021
Q4 		$222K Buy
10,324
+134
+1% +$5.78K 0.22% 93
2021
Q3 		$753K Sell
10,190
-6,494
-39% -$433K 0.49% 51
2021
Q2 		$912K Buy
+16,684
New +$998K 0.39% 76

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Connacht Asset Management's ALXO Position: Q3 2022 in Review

Connacht Asset Management sold out of ALX Oncology (ALXO) in Q3 2022, closing a stake of 20,953 shares — an estimated $170K sold.

Connacht Asset Management first reported a position in ALXO in Q2 2021 and held it in 5 quarters. The position peaked at $912K in Q2 2021. 99 funds tracked by Wall St. Rank hold ALXO as of Q3 2022.

  • Connacht Asset Management reported no remaining ALX Oncology position as of Q3 2022 after selling out during the quarter.
  • Connacht Asset Management sold 20,953 ALX Oncology shares in Q3 2022, an estimated $170K.
  • Connacht Asset Management first reported a position in ALX Oncology in Q2 2021 and held it in 5 quarters.
  • Connacht Asset Management's ALX Oncology position peaked at $912K in Q2 2021.
  • 99 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2022.

Based on Connacht Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.